ORIC — ORIC Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: ORIC Pharmaceuticals Q1 Net Income USD -30.021 Million
Oric Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview
Brief: ORIC Pharmaceuticals Presents Preclinical Data To Support The Potential Of Oric-944 As A Best-In-Class PRC2 Inhibitor For The Treatment Of Prostate Cancer
U.S. RESEARCH ROUNDUP-Intuit, Itron, Workday
U.S. RESEARCH ROUNDUP-Axsome Therapeutics, Penumbra, Republic Services
Brief: ORIC Pharmaceuticals Q4 Net Income USD -36.307 Million
Brief: Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-Conmed, McKesson, Veralto
Brief: ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114
Brief: ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Oric Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: ORIC Pharmaceuticals Q3 Net Income USD -34.566 Million
Brief: Openbench And Oric Pharmaceuticals Launch Success-Driven Discovery Collaboration
Oric Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: ORIC Pharmaceuticals Q2 Net Income USD -31.963 Million
Oric Pharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview
Oric Pharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview
Brief: Oric Pharmaceuticals Expands Leadership Team With Appointment Of Keith Lui As Senior Vice President Of Commercial And Medical Affairs
Brief: ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners